Axogen Presents Prostate Nerve Reconstruction Market Launch Plans

By Public Technologies
  • Axogen is moving forward with a prostate nerve reconstruction market launch using Avance nerve grafts.
  • The presentation estimates a $754 million total addressable market, with a weighted average selling price of approximately $7,000 per procedure.
  • Clinical experience includes more than 220 reconstructed patients across 15 sites; 117 patients had at least six months of follow-up.
  • At six months, approximately 80% had better-than-expected erectile function; more than 95% had regained continence.
  • A hospital administrator survey found 56% would support adoption before broad insurance coverage.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Axogen Inc. published the original content used to generate this news brief on November 09, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.